Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shieldin complex subunit 2 (SHLD2) is a core component of the shieldin complex, which also includes SHLD1, SHLD3, and REV7. The complex acts downstream of 53BP1–RIF1 in DNA double-strand break repair, suppressing end resection and favoring repair via the non-homologous end joining (NHEJ) pathway while inhibiting homologous recombination. SHLD2 possesses a critical N-terminal domain necessary for its recruitment to DNA breaks and a C-terminal OB-fold domain capable of direct DNA binding. Shieldin, through its DNA end-protection activity, is crucial for immunoglobulin class-switch recombination, telomere fusion, and genome integrity. Loss of SHLD2 function shifts DNA repair toward homologous recombination and can confer resistance or sensitivity to DNA-damaging therapies such as PARP inhibitors, making it of interest in BRCA1-deficient cancers.
No known direct-drug interactions; modulators targeting SHLD2 would likely influence DNA repair pathway usage (e.g., promote sensitivity to PARP inhibitors via synthetic lethality when SHLD2 is lost)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shieldin complex subunit 2 (SHLD2).